(Q37271928)

19 August 2017

1 reference

title

Systemic cancer therapy: evolution over the last 60 years (English)

1 reference

19 August 2017

1

Grace K Dy

1 reference

19 August 2017

2

Alex A Adjei

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

113

1 reference

19 August 2017

issue

7 Suppl

1 reference

19 August 2017

page(s)

1857-1887

1 reference

Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

EXPERIMENTAL AND CLINICAL STUDIES ON THE TREATMENT OF CANCER BY DICHLORETHYLSULPHIDE (MUSTARD GAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Timeline: Chemotherapy and the war on cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Predicting the course of Gompertzian growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Role of Toll-like receptors in antisense and siRNA [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Nucleic Acid Aptamers as Tools and Drugs: Recent Developments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Escort aptamers: a delivery service for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The protein kinase complement of the human genome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Structure of the extracellular region of HER3 reveals an interdomain tether

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

A structure-based model for ligand binding and dimerization of EGF receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cetuximab and radiotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Oncogenic derivatives of platelet-derived growth factor receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

CTLA-4 can function as a negative regulator of T cell activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The role of the CTLA4 blockade in the treatment of malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Oncogenic Ras in tumour progression and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

A tagging-via-substrate technology for detection and proteomics of farnesylated proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The proteasome: a suitable antineoplastic target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

TSC2 mediates cellular energy response to control cell growth and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

eIF4E--from translation to transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Targeting von Hippel-Lindau pathway in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The epigenomics of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Histone deacetylase inhibitors: overview and perspectives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Histone deacetylase inhibitors specifically kill nonproliferating tumour cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The RXR heterodimers and orphan receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Co-regulator recruitment and the mechanism of retinoic acid receptor synergy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

The promise of retinoids to fight against cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Antisense oligonucleotides as therapeutic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Bradycardia during therapy for multiple myeloma with thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Molecularly targeted oncology therapeutics and prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Effects of retinoic acid on the immune system: Stimulation of T killer cell induction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Central hypothyroidism associated with retinoid X receptor-selective ligands

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cetuximab therapy and symptomatic hypomagnesemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Demonstration of an activation regulated NF-kappaB/I-kappaBalpha complex in human platelets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Adverse effects of thalidomide administration in patients with neoplastic diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Thalidomide neuropathy in patients treated for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.23651

1 reference

7 January 2021

Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23651

7 January 2021

Identifiers

DOI

10.1002/CNCR.23651

1 reference

19 August 2017

1 reference